Login
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc.

minervaneurosciences.com

What Do They Do?

Develops roluperidone to treat negative symptoms in people with schizophrenia and other drug candidates for central nervous system diseases.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ Turned profitable
vs −$2.7M in Q3 FY2025

Who Do They Compete With?

Competes with GlaxoSmithKline, Sanofi-Aventis, Janssen, Novartis, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Intra-Cellular Therapies, Karuna Therapeutics, Acadia Pharmaceuticals, Lundbeck, Reviva Pharmaceuticals, SyneuRx, Neurocrine, and Denovo Biopharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support